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Abstract: Cigarette smoking is an established cause of lung cancer. However, pulmonary 
fibrosis is also an independent risk factor for the development of lung cancer. Smoking-related 
interstitial fibrosis (SRIF) has recently been reported. We hypothesized that adenocarcinomas 
in lungs with SRIF might show distinct molecular changes and examined the molecular phe-
notype of 168 resected lung adenocarcinomas in lungs with and without SRIF. The diagnosis 
of SRIF was determined by histological examination, based on the presence of alveolar septal 
thickening, due to pauci-inflamed, hyalinized, “ropy” collagen, in areas of lung greater than 1 
cm away from the tumor. Tumors were concomitantly examined genotypically for mutations in 
genes frequently altered in cancer, including EGFR and KRAS, by SNaPshot and by fluorescence 
in situ hybridization for possible ALK rearrangements. Fluorescence in situ hybridization for 
ROS1 rearrangement (n=36) and/or MET amplification (n=31) were performed when no muta-
tion was identified by either SNaPshot or ALK analysis. Sixty-five cases (38.7%) showed SRIF, 
which was distributed in all lobes of the lungs examined. No differences were observed in sex, 
average age, or smoking history in patients with and without SRIF. There was no difference in 
either the percent or types of adenocarcinoma genetic mutations in patients with SRIF versus 
those without. This data suggests that SRIF does not represent an independent risk factor for the 
development of the major known and targeted mutations seen in pulmonary adenocarcinoma. 
However, additional research is required to investigate the potential significance of SRIF in the 
pathogenesis of lung cancer.
Keywords: lung, cancer, smoking, SRIF
Introduction
Cigarette smoking is the leading cause of lung carcinoma. Lung cancer has also been 
linked to various fibrosing lung diseases, including idiopathic pulmonary fibrosis (IPF), 
systemic sclerosis, and dermatomyositis, and certain pneumoconioses (eg, asbestosis 
and silicosis) such that pulmonary fibrosis may represent an independent risk factor 
for developing lung cancer.1–4 However, the role of pulmonary fibrosis in pathogen-
esis of lung cancer has not been elucidated. Recently, investigators have described a 
distinct type of pulmonary interstitial fibrosis in smokers, smoking-related interstitial 
fibrosis (SRIF). SRIF is characterized by the presence of alveolar septal thickening 
by hyalinized collagen with little associated inflammation and is histologically dis-
tinguishable from other fibrosing lung diseases.5,6 Furthermore, pulmonary fibrosis 
associated with emphysema has been recognized as a pattern of lung abnormality in 
the radiographic imaging of smokers and has been associated with an increased risk of 
lung cancer in prior studies.7–10 Thus, we hypothesized that SRIF might be associated International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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with lung cancer with specific genetic alterations. For this 
reason, we interrogated multiple genes for patterns of muta-
tions in lung adenocarcinomas in patients with concomitant 
evidence of SRIF.
Materials and methods
Case selection
The files of the James Homer Wright Pathology Laboratory 
of the Massachusetts General Hospital were searched for lung 
specimens resected between 2008 and 2012 with the diagnosis 
of pulmonary adenocarcinoma. Only cases in which a sub-
stantial portion of lung parenchyma uninvolved by tumor was 
resected (ie, large wedge resections, multiple wedge resec-
tions, segmentectomies, lobectomies, or pneumonectomies) 
were included. Additionally, only cases with tumors on which 
genetic testing had been performed for clinical purposes were 
included. Specimens resected from nonsmokers and patients 
with a prior history of neoadjuvant radiation therapy were 
excluded. A smoking history was obtained from the patients’ 
medical records and based on self-reporting. If available, 
imaging studies were reviewed.
histologic evaluation
Two pathologists (AP and RLK) retrospectively examined 
hematoxylin and eosin (H&E)-stained sections of lung paren-
chyma uninvolved by and distant from tumor in order to evalu-
ate for emphysema and SRIF. The number of slides examined 
was between two and ten per case, depending on the size of 
the resection specimen and extent of tumor involvement. The 
criteria used for the diagnosis of SRIF were the presence of 
paucicellular, eosinophilic, collagenous thickening of alveolar 
septae in at least 30% of the examined lung parenchyma that 
was uninvolved by tumor (specifically, .1 cm away from the 
tumor), with no identified confounding cause.   Respiratory 
bronchiolitis was defined by the presence of pigmented 
(smoker’s) macrophages within the respiratory bronchioles 
and/or surrounding peribronchiolar alveoli.
Mutational analysis
Tumors (n=168) were examined genotypically for 71 hot spot 
mutations in 14 genes frequently altered in cancers (includ-
ing AKT1, APC, BRAF , B-catenin, EGFR, IDH1, KIT, KRAS, 
MAP2K1, NOTCH1, NRAS, PIK3CA, PTEN, and TP53) by 
SNaPshot (Applied Biosystems, Foster City, CA, USA), 
a previously described mutational analysis assay.11 Briefly, 
DNA from formalin-fixed, paraffin-embedded tissue was sub-
jected to a multiplexed polymerase chain reaction (PCR) and 
single-base extension reaction platform in order to   generate 
fluorescently labeled signals that interrogate hot-spot mutation 
sites. The SNaPshot products were then analyzed by capillary 
electrophoresis to determine selected hot-spot mutations. In 
addition, direct PCR sequencing techniques were used to 
assay EGFR exons 19 and 20 and ERBB2 (HER2) exon 20 
for in-frame activating insertions or deletions.
Fluorescence in situ hybridization (FISH) was performed 
on deparaffinized, protease-treated, 5 µm thick sections cut 
from tumor material from most cases (n=162) in order to 
evaluate for the presence of ALK rearrangement. H&E-
stained slides were reviewed to select regions of the tissue 
that contain mostly tumor cells to be used for hybridization. 
Dual-color break-apart probes, constructed from BAC clones, 
specific for the 3′ and 5′ sequences of the ALK gene were 
hybridized according to the manufacturer’s protocol using a 
Hybrite slide processor (Abbott Molecular, Des Plaines, IL, 
USA). A case was considered positive for ALK rearrangement 
if 15% of cells contained split fluorescent signals.
In tumors in which no mutation was identified by the 
SNaPshot assay and no ALK rearrangement was present, 
FISH for ROS1 rearrangement (n=36) and/or FISH for MET 
amplification (n=31) were performed. The presence of ROS1 
rearrangement was evaluated using a protocol identical to 
that described for ALK FISH, with ROS1-specific 3′ and 5′ 
sequence probes. To analyze MET gene amplification status, 
deparaffinized, protease-treated, 5 µm thick sections cut from 
tumor material (as selected based on review of H&E-stained 
slides) were hybridized with dual-color probes for the MET 
locus and centromere on chromosome 7 according to the man-
ufacturer’s protocol using a Hybrite slide processor (Abbott 
Molecular). MET amplification was considered present when 
the MET: centromere 7 signal ratio was 2.2 or greater.
statistical analysis
The difference in age and smoking history in patients with 
and without SRIF was compared by means of an unpaired 
t-test. The Fisher’s exact test was used to compare the sex 
distribution, presence of emphysema, and distribution of 
examined parenchyma in cases with and without SRIF. 
The presence of genetic alterations in evaluated genes was 
compared between lung adenocarcinoma cases with and 
without background SRIF using the Fisher’s exact test. Two-
tailed P-values less than 0.05 were considered statistically 
significant.
Results
One hundred and sixty-eight lung adenocarcinoma resec-
tions were included in the study; these included four wedge International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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  resections, four with multiple wedge resections, four segmen-
tectomies, two partial lobectomies, 144 lobectomies, and ten 
pneumonectomies. The number of H&E-stained slides from 
lung parenchyma uninvolved by and at a distance greater than 
1 cm from the pulmonary malignancy that were examined 
varied from two to ten per case. On histologic review, 65 
cases (38.7%) showed SRIF in the lung uninvolved by tumor; 
103 (61.3%) cases did not show SRIF. In cases with SRIF, 
alveolar septal fibrosis with dense, eosinophilic, paucicellular 
collagen bundles was present in the subpleural lung parenchyma 
with centrilobular peribronchiolar accentuation (Figure 1). The 
findings of SRIF were distributed in all lung lobes (Table 1). 
Among cases with SRIF, 61 (93.8%) had concomitant emphy-
sema on histologic examination. In these cases, SRIF was seen 
both in and away from the emphysematous lung parenchyma. 
In contrast, 85 (82.5%) patients without SRIF had emphysema 
on histologic exam (P=0.04). Of note, all cases showed patchy 
evidence of respiratory bronchiolitis.
A history of cigarette smoking was documented in all 
cases. The smoking history elicited from patients with and 
without SRIF was 39.8±19.8 pack years and 37.5±22.5 
pack years, respectively (P=0.41) (Table 1). The average 
age at resection among patients with and without SRIF was 
66±8 years and 67±10 years, respectively (P=0.85). There 
was no significant difference in the sex of patients with 
or without SRIF (70.8% vs 62.1%, respectively; P=0.32). 
Results of imaging studies were not consistently available 
for review; however, few patients had evidence of SRIF on 
computed tomography (CT) evaluation (Figure 2).
genetic analysis
One of three sequentially updated versions of SNaPshot and 
direct PCR sequencing assays were performed on 64 cases 
with SRIF and 102 cases without SRIF. ALK FISH, ROS 
FISH, and MET FISH were performed on 64, 16, and 13 cases 
with SRIF, respectively, and on 99, 20, and 18 cases without 
SRIF, respectively. There was no difference in the number 
of mutations present in each of the 14 interrogated genes or 
in the prevalence of individual hotspot mutations in cases 
with and without SRIF. Mutations in EGFR were observed in 
9 (14.1%) cases with SRIF and 19 (18.6%) cases without SRIF 
(P=0.53); mutations in KRAS occurred in 24 (37.5%) cases 
with SRIF and in 50 (49.0%) cases without SRIF (P=0.15) 
(Table 1). Finally, there was no difference in the number of 
cases with and without SRIF in which no genetic mutation 
was identified (27 and 30, respectively; P=0.13).
Discussion
SRIF was present in the background lung parenchyma of 38.7% 
of lungs from smokers with pulmonary adenocarcinoma. This 
is comparable to other recently reported studies of SRIF.12–15 
Katzenstein et al evaluated lobectomy specimens resected for 
a malignant neoplasm in 20 smokers and identified patchy 
widening of alveolar septa by acellular collagen deposi-
tion with minimal or focal associated inflammation in 45% 
of cases.12 SRIF was predominantly subpleural, but also 
occurred with or without associated emphysema in deep lung 
parenchyma in a centrilobular distribution, as in the present 
study. Similar lesions had previously been described in up 
to 50% of smokers, although authors have ascribed different 
terms to comparable histologic findings, including “respira-
tory bronchiolitis-associated interstitial lung disease with 
fibrosis” and “airspace enlargement with fibrosis”.13–15 These 
interstitial changes were absent in nonsmokers and must 
be distinguished from other fibrosing interstitial lung dis-
eases, including IPF and nonspecific interstitial pneumonia, 
Figure 1 (A) Smoking-related interstitial fibrosis involving subpleural lung parenchyma (pleural surface is at the left) with centrilobular accentuation (arrow); (B) thickening 
of the alveolar septa by dense, eosinophilic, paucicellular collagen bundles.International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
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Figure 2 Spiculated nodule in the left upper lobe (arrow in A) with associated 
18-FDg uptake on positron emission tomography scan (B), consistent with lung 
cancer.
Notes: Note subtle centrilobular nodules (arrowhead) and subpleural reticulation 
and ground glass opacity (arrow) on the computed tomography scan (A), consistent 
with smoking-related interstitial fibrosis.
Table 1 Clinical and pathologic features of pulmonary adenocar-
cinoma cases with and without srIF
Features With SRIF 
(n=65)
Without SRIF 
(n=103)
P-value
Female 46 (70.8%) 64 (62.1%) ns
Male 19 (29.2%) 39 (37.9%) ns
average age (years) 66±8 67±10 ns
smoking history  
(pack-years)
39.8±19.8 37.5±22.5 ns
emphysema 61 (93.8%) 85 (82.5%) 0.04
Distribution of examined uninvolved lung parenchyma
  Right upper lobe 23 (35.4%) 33 (32.0%) ns
  Right middle lobe 6 (9.2%) 5 (4.9%) ns
  Right lower lobe 10 (15.4%) 19 (18.4%) ns
  Left upper lobe 13 (20.0%) 22 (21.4%) ns
  Left lower lobe 6 (9.2%) 14 (13.6%) ns
  Unspecified lobe 7 (10.8%) 10 (9.7%) ns
EGFR mutations* 9 (14.1%) 19 (18.6%) ns
KRAS mutations* 24 (37.5%) 50 (49.0%) ns
Note: *Of 64 cases with srIF and 102 cases without srIF.
Abbreviations: NS, not significant; SRIF, smoking-related interstitial fibrosis.
which have other important clinical implications.4,5,13–15 The 
distinction of SRIF from other chronic interstitial fibrosing 
lesions not only has prognostic implications but also affects 
therapeutic interventions.
While SRIF seems to be a common finding in smokers, 
clinical symptoms and radiologic findings associated with 
this pattern of interstitial lung disease are uncommon.12–14 
However, the index group of patients with SRIF described by 
Yousem et al presented with signs and symptoms of chronic 
interstitial lung disease and, for this reason, underwent lung 
biopsy.13 Katzenstein et al identified mild to moderate reduc-
tion in diffusion capacity in four of nine (44%) patients with 
SRIF who underwent pulmonary function testing.12 Notably, 
several radiology studies have reviewed CT findings in 
smokers and found subtle interstitial changes in a subset 
of smokers. Lederer et al found ground glass and reticular 
opacities on CT scan in 2.2% of smokers, with increasing 
numbers of these areas in patients with increasing pack 
years.16 More recently, Washko et al and Sverzellati et al 
reported interstitial lung abnormalities in 8% and 22.8% 
of smokers, respectively.17,18 Thus, while SRIF is often an 
incidental finding recognized in lung parenchyma, these 
studies suggest that the increasing use of high-resolution CT 
may increase the detection of interstitial lung abnormalities 
in asymptomatic smokers and lung biopsies may be utilized 
to provide insight into the etiology of a patient’s pulmonary 
interstitial abnormalities.
It is possible that SRIF is part of the spectrum of changes 
seen in emphysema as, in this study, emphysema was more often 
present in cases with SRIF than in those without SRIF. Smokers 
with both pulmonary fibrosis and emphysema have been previ-
ously described.7,19–22 Cottin et al coined the term “combined 
pulmonary fibrosis and emphysema” (CPFE) in a retrospective 
study of 61 patients with upper lobe emphysema and lower 
lobe pulmonary fibrosis on high-resolution CT scan.7 Notably, 
CPFE has been associated with an increased risk of lung cancer. 
Kitaguchi et al reported a 46.8% prevalence of lung cancer 
in patients with CPFE as compared to 7.3% in patients with 
chronic obstructive pulmonary disease alone.8 More recently, 
Usui et al evaluated 1,143 consecutive patients with primary 
lung carcinoma and found that 8.9% had evidence of CPFE International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
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on CT scan at the time of cancer diagnosis.9 This association 
between CPFE and lung cancer may reflect the importance of 
cigarette smoking as a predisposing factor. However, the pres-
ence of interstitial fibrosis might be an independent factor in 
the development and progression of lung cancer.9,10
In 1939, Friedrich23 first proposed the association between 
pulmonary fibrosis and lung cancer. Subsequent studies have 
supported this relationship.2–4 IPF has been implicated as an 
independent risk factor for the development of lung cancer, 
although there is an increased incidence of IPF in smokers.1,24–30 
Furthermore, molecular studies have demonstrated the pres-
ence of genetic alterations, especially in tumor suppressor genes 
such as p53, within lung tissue from patients with IPF.31–36 Thus, 
it is hypothesized that repeated inflammation, injury, and repair 
of the lung parenchyma may predispose to the development of 
lung cancer. More recently, inappropriate cytokine signaling 
has been implicated as a causative mechanism of IPF and may 
play a role in pulmonary carcinogenesis.37
Lung cancer in the setting of ILD is the most common 
malignancy to develop in patients with systemic sclerosis.38–42 
Similarly to IPF, lung cancer in these patients may result 
from cellular injury and genetic damage caused by contin-
ued pulmonary inflammation and fibrosis. In addition, other 
rheumatologic diseases, such as dermatomyositis, rheumatoid 
arthritis, systemic lupus erythematosus, and sarcoidosis, 
and pneumoconioses, including asbestosis, silicosis, and 
berylliosis, have been associated with an increased risk of 
the development of lung cancer.2–4 Notably, although the lit-
erature is controversial, studies have suggested that, among 
patients with asbestosis, there is an increased prevalence of 
tumors within the lower lung lobes; ie, in the most fibrotic 
regions of the lung parenchyma.43,44
In light of the strong association of pulmonary fibrosis 
and lung cancer, we hypothesized that SRIF might be associ-
ated with a distinct molecular pathway in the development 
of lung cancer in smokers, despite the underlying relation-
ship between both SRIF and cancer with cigarette smoking. 
Recent studies have showed an inverse relationship between 
the presence of interstitial lung disease and EGFR mutations 
in associated lung tumors.45,46 However, unlike our study, 
these studies did not specifically evaluate the role of SRIF 
in cancer progression, as both smokers and nonsmokers and 
patients with multiple subtypes of interstitial fibrosis were 
included in these studies. We found no difference in the 
number or types of genetic mutations in adenocarcinomas 
that develop in lungs with and without SRIF, which suggests 
that there is no difference in the molecular pathogenesis of 
adenocarcinomas that arise within smokers in the presence 
of SRIF. However, due to the limited sample size, additional 
research must be done to further investigate the potential 
clinical significance of SRIF and subsequent impact on 
cancer progression. In addition, the mechanism by which 
other fibrosing lung diseases, such as IPF, can lead to cancer 
development must be clarified.
This study has several limitations. Firstly, information 
regarding results of pulmonary function tests and imaging 
studies were not consistently available for review. A compari-
son of the mutations present in tumors from patients in our 
cohort with normal and abnormal lung function and those 
with and without evidence of interstitial fibrosis on imaging 
may have proved insightful. Secondly, this study was retro-
spective and nonrandomized. Most mutations, such as rear-
rangements in ALK and ROS, occurred in only small subsets 
of lung adenocarcinomas, so that it was not possible to make 
statistically relevant conclusions concerning these cases. A 
prospective randomized controlled study with systematic 
sampling of both subpleural and deep lung parenchyma away 
from the tumor would allow for more accurate assessment of 
the presence of SRIF. In addition, limited numbers of genes 
were included in the SNaPshot and FISH analysis that were 
performed, such that other mutations of possible relevance 
were not interrogated. Future studies adopting broad next-
generation sequencing techniques may yield greater insight 
into the possible role of SRIF in the pathways of carcino-
genesis. It is, of course, possible that the same carcinogens 
that lead to mutations in the lung epithelial genome are 
responsible for SRIF, but this remains to be investigated. 
However, despite the limitations of the present study, it is, to 
our knowledge, the first to explore the possible relationship 
between SRIF and the pathogenesis of lung cancer.
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